A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 08 Mar 2018
At a glance
- Drugs IMX-110 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Immix Biopharma Australia
- 27 Feb 2018 Status changed from not yet recruiting to recruiting.
- 05 Jan 2018 According to an Immix Biopharma media release, Professor de Souza from Western Sydney University is the principal investigator for this study.
- 05 Jan 2018 According to an Immix Biopharma media release, Human Research Ethics Committee (IRB) approval has been recieved for this study.